Business Jan 10, 2017
Takeda Pharmaceutical to buy U.S. cancer drugmaker Ariad in $4.66 billion deal
Takeda Pharmaceutical Co. will expand its footprint in the U.S. oncology market with the $4.66 billion purchase of Ariad Pharmaceuticals Inc. The deal will add one potential blockbuster in lung cancer and another already on-the-market therapy. Takeda will pay $24 a share for Ariad, the ...